tuneTypical Dose
120-240 mg per day (standardized EGb 761 extract)
Natural Compound
Ginkgo Biloba
Ginkgo biloba
Evidence TierBWADA NOT PROHIBITED
watchEffect Window
6-8 weeks minimum for cognitive effects. 12-24 weeks for full dementia-related outcomes.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Standardized Ginkgo biloba extract can modestly improve cognition and daily functioning in mild dementia, but it is not a dementia-prevention supplement and the evidence is formulation specific.
The strongest modern evidence for ginkgo is symptom management in mild dementia with standardized EGb 761, where benefits are modest and not preventive. Evidence for tinnitus and broad circulation claims remains inconsistent. Bleeding risk and interaction burden still matter, especially with antiplatelet or anticoagulant therapy.
Vasorelaxant that increases cerebral and peripheral blood flow via PAF antagonism. Standardized EGb 761 extract provides antioxidant and neuroprotective effects through ROS scavenging and mitochondrial protection.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Modest cognitive improvement in elderly with existing cognitive decline (B-tier)
- Improved cerebral blood flow via PAF antagonism (B-tier)
- No benefit for dementia prevention in healthy elderly (negative mega-trials)
Secondary Outcomes
- Increased pain-free walking distance in peripheral arterial disease (C-tier)
- Weak and inconsistent evidence for cognition in healthy young adults (C-tier)
Safety
Contraindications and Interactions
Contraindications
- Bleeding disorders or high bleeding risk
- Planned surgery (discontinue at least 2 weeks prior)
- Seizure disorders
- Pregnancy
- Lactation
Side effects
- Headache
- Nausea or dyspepsia
- Constipation
- Diarrhea
- Dizziness
- Increased appetite
- Increased bleeding tendency
- Allergic skin reactions, including contact dermatitis
- Rare severe skin eruptions reported in case studies
Interactions
- Anticoagulants/antiplatelets, including warfarin, aspirin, heparin (additive bleeding risk)
- Anticonvulsants (ginkgotoxin may reduce seizure threshold)
- CYP2C19 substrates (possible blood-level changes)
- CYP3A4 substrates, including protease inhibitors, some statins, and calcium channel blockers (possible blood-level changes. Reduced efficacy reported for some agents)
- CYP2C9 substrates, including NSAIDs, phenytoin (possible blood-level changes)
- Atorvastatin (possible minor exposure reduction, unclear clinical impact)
- Alprazolam (possible minor exposure reduction, usually not clinically significant)
- Supplements metabolized by CYP2C19/CYP3A4 (possible blood-level changes)
Avoid if
- Active bleeding conditions
- Surgery within 2 weeks
- Uncontrolled epilepsy or seizure-prone states
- Pregnancy
- Lactation
Evidence
Study-level References
ginkgo-biloba-SRC-000Meta-analysis of randomized controlled trials
Sourceopen_in_newRiepe M, Hoerr R, Schlaefke S. Ginkgo biloba extract EGb 761 is safe and effective in the treatment of mild dementia - a meta-analysis of patient subgroups in randomised controlled trials. World J Biol Psychiatry. 2025;26(3):119-129. doi:10.1080/15622975.2024.2446830. PMID:39895346.
Population: Patients with mild dementia pooled from four eligible randomized placebo-controlled EGb 761 trials.
Dose protocol: 240 mg/day EGb 761 across four pooled placebo-controlled dementia trials
Key findings: Improved cognition, global assessment, activities of daily living, and quality of life in mild dementia without higher adverse-event rates.
Notes: Best current anchor for symptomatic mild-dementia use. Does not support prevention claims.
Paper content
This 2025 meta-analysis narrows the honest clinical use case for ginkgo. In patients who already have mild dementia, 240 mg/day of EGb 761 improved cognition, daily functioning, global assessment, and quality of life versus placebo without raising adverse events. It does not support prevention in healthy adults, but it does support modest symptomatic use in established cognitive decline.
ginkgo-biloba-SRC-001Meta-analysis of RCTs
Sourceopen_in_newWeinmann S, et al. "Effects of Ginkgo biloba in dementia: systematic review and meta-analysis." BMC Geriatr. 2010.
Population: Patients with Alzheimer's, vascular, or mixed dementia
Dose protocol: 120-240 mg/day EGb 761 for 22-26 weeks
Key findings: EGb 761 at 240 mg/day was effective and safe in dementia treatment, showing significant superiority over placebo in cognition (SKT, ADAS-cog) and activities of daily living. Effect size comparable to but slightly smaller than cholinesterase inhibitors.
Paper content
EGb 761 at 240 mg/day was effective and safe in dementia treatment, showing significant superiority over placebo in cognition (SKT, ADAS-cog) and activities of daily living. Effect size comparable to but slightly smaller than cholinesterase inhibitors.
ginkgo-biloba-SRC-002Randomized Controlled Trial (n=2854)
Sourceopen_in_newVellas B, et al. "Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial." Lancet Neurol. 2012;11(10):851-9.
Population: Healthy elderly (≥70 years) with memory complaints
Dose protocol: 120 mg EGb 761 twice daily for 5 years
Key findings: Ginkgo biloba did not reduce the risk of progression to Alzheimer's disease compared to placebo over 5 years. This large prevention trial effectively disproved the dementia prevention hypothesis for ginkgo in healthy elderly.
Paper content
Ginkgo biloba did not reduce the risk of progression to Alzheimer's disease compared to placebo over 5 years. This large prevention trial effectively disproved the dementia prevention hypothesis for ginkgo in healthy elderly.
ginkgo-biloba-SRC-003Cochrane Systematic Review
Sourceopen_in_newBirks J, Grimley Evans J. "Ginkgo biloba for cognitive impairment and dementia." Cochrane Database Syst Rev. 2009;(1):CD003120.
Population: Patients with cognitive impairment or dementia
Dose protocol: Various EGb 761 regimens
Key findings: Modest benefit in existing dementia patients for cognition and ADLs, comparable to or slightly less than cholinesterase inhibitors. Evidence is inconsistent across trials and limited by heterogeneity in study design and outcome measures. Clinical significance of observed improvements is debated.
Paper content
Modest benefit in existing dementia patients for cognition and ADLs, comparable to or slightly less than cholinesterase inhibitors. Evidence is inconsistent across trials and limited by heterogeneity in study design and outcome measures. Clinical significance of observed improvements is debated.
ginkgo-biloba-SRC-004Cochrane systematic review and meta-analysis.
Sourceopen_in_newWieland LS, Ludeman E, Chi Y, Feinberg TM, Chen IH, Chen KH, Zhu Y, Wolverson E, Amri H. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2026;2(2):CD013661. doi:10.1002/14651858.CD013661.pub2. PMID:41641880.
Population: Adults with cognitive complaints, mild cognitive impairment, multiple sclerosis with cognitive impairment, or dementia diagnoses.
Dose protocol: Cochrane review pooling 82 studies (10,613 participants) of ginkgo biloba extract versus placebo or usual treatment.
Key findings: Small to moderate benefits in dementia at 6 months for global status, cognition, and ADLs (low to moderate certainty). Little or no effect in MCI (moderate certainty). Safety comparable to placebo.
Notes: Definitive 2026 Cochrane review. Supersedes earlier meta-analyses and confirms the dementia-only benefit pattern.
Paper content
This 2026 Cochrane systematic review is the most comprehensive assessment of ginkgo biloba for cognitive impairment and dementia to date, pooling 82 studies with over 10,000 participants. For dementia populations at six months, ginkgo showed small to moderate benefits in global clinical status, cognitive function, and activities of daily living, though evidence certainty was low to moderate. For mild cognitive impairment, ginkgo demonstrated little or no effect on any measured outcome with moderate-certainty evidence. Safety profiles were comparable to placebo across populations. This review supersedes earlier meta-analyses and provides the strongest current anchor for ginkgo's role as a symptomatic treatment in existing dementia rather than a preventive or MCI intervention.
ginkgo-biloba-SRC-005Systematic review and network meta-analysis.
Sourceopen_in_newTiemtad et al. Comparative effects of Bacopa monnieri and Ginkgo biloba on cognitive functions: A systematic review and network meta-analysis. Phytomedicine. 2026;153:157915. doi:10.1016/j.phymed.2026.157915. PMID:41678913.
Population: Healthy adults from 29 randomized controlled trials.
Dose protocol: Network meta-analysis of 29 RCTs (2,107 healthy adults) comparing Bacopa monnieri and Ginkgo biloba at high and low doses.
Key findings: Ginkgo biloba at both dose levels ranked below high-dose Bacopa monnieri across most cognitive domains in healthy adults. Confirms limited cognitive benefit of ginkgo in non-dementia populations.
Notes: Indirect comparisons only (no direct head-to-head Bacopa vs ginkgo trials). Useful for contextualing ginkgo's weak healthy-adult signal.
Paper content
This network meta-analysis compared Bacopa monnieri and Ginkgo biloba at different dose levels for cognitive function in 2,107 healthy adults across 29 RCTs. High-dose Bacopa (600 mg/day or more) ranked highest for working memory (SUCRA 100%, SMD 1.84 to 2.04 vs comparators). Ginkgo biloba at both dose levels showed lower rankings across most cognitive domains in healthy populations. This is relevant to ginkgo evidence because it confirms the pattern seen in other reviews: ginkgo's cognitive benefit is primarily in dementia populations, not healthy adults. The study fills a comparative gap by directly ranking herbal nootropics, though the lack of direct head-to-head trials between Bacopa and ginkgo limits confidence in the comparative rankings.